These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 31899150

  • 1. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
    Wu T, Kasper S, Wong RM, Bracken B.
    Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150
    [Abstract] [Full Text] [Related]

  • 2. Impact of Oxidative Stress Biomarkers and Carboxymethyllysine (an Advanced Glycation End Product) on Prostate Cancer: A Prospective Study.
    Yang S, Pinney SM, Mallick P, Ho SM, Bracken B, Wu T.
    Clin Genitourin Cancer; 2015 Oct; 13(5):e347-51. PubMed ID: 25972296
    [Abstract] [Full Text] [Related]

  • 3. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L, Hu X, Zhu Y, Lu J, Xu Y, Wang G, Guo J.
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M, Ma T, Li J, Zhang HJ, Li Q, Wang JJ, Sang T, Cao CL, Cui XW.
    Med Sci Monit; 2021 Feb 08; 27():e929913. PubMed ID: 33556045
    [Abstract] [Full Text] [Related]

  • 5. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, Huland E, Huland H, Lilja H.
    J Urol; 2003 Dec 08; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [Abstract] [Full Text] [Related]

  • 6. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J.
    BJU Int; 2007 Jan 08; 99(1):41-5. PubMed ID: 17227490
    [Abstract] [Full Text] [Related]

  • 7. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

  • 8. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV, Guseinov RG, Skryabin ON, Orlov IN, Martov AG.
    Urologiia; 2018 Jul 01; (3):92-97. PubMed ID: 30035426
    [Abstract] [Full Text] [Related]

  • 9. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R.
    Urology; 1998 Sep 01; 52(3):360-5. PubMed ID: 9730444
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA.
    Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV.
    Prostate; 2008 Mar 01; 68(4):442-52. PubMed ID: 18196514
    [Abstract] [Full Text] [Related]

  • 13. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
    Nyame YA, Wilkins L, Greene DJ, Ganesan V, Dai C, Almassi N, Stephenson AJ, Gong M, Berglund R, Klein EA.
    Prostate Cancer Prostatic Dis; 2019 Dec 01; 22(4):617-623. PubMed ID: 30996285
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
    Herden J, Weissbach L.
    World J Urol; 2018 Mar 01; 36(3):383-391. PubMed ID: 29330583
    [Abstract] [Full Text] [Related]

  • 16. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 01; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 17. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H, Graefen M.
    Eur Urol; 2015 Aug 01; 68(2):175-8. PubMed ID: 25736732
    [Abstract] [Full Text] [Related]

  • 18. Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma.
    Misraï V, Pasquie M, Bordier B, Guillotreau J, Gryn A, Palasse J, Bruguière E, Pradere B, Rouprêt M, Zorn KC.
    World J Urol; 2020 Apr 01; 38(4):993-1000. PubMed ID: 31139906
    [Abstract] [Full Text] [Related]

  • 19. Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer.
    Koike A, Robles BEF, da Silva Bonacini AG, de Alcantara CC, Reiche EMV, Dichi I, Maes M, Cecchini R, Simão ANC.
    Sci Rep; 2020 Jun 04; 10(1):9093. PubMed ID: 32499542
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.